hotspot -WSS

hotspot

author：comprehensive 2025-09-06 04:42:09 - browse：2169

Vertex Pharmaceuticals - sunset — Bill Sikes/AP

Vertex Pharmaceuticals has spent decades trying to develop molecules that reduce pain safely and potently, searching for success in a field its own executives have dubbed a graveyard for drug discovery. Detailed data published Wednesday lent support to that quest, with a pair of company-sponsored clinical trials showing an experimental non-opioid therapy reduced pain after surgery.

The drug, VX-548, blocks signals from pain-sensitive neurons before those electrical messages reach the brain. And in a pair of randomized trials, patients given a high dose of the oral medication after bunion surgery or abdominoplasty (a tummy tuck) reported less pain than those given a placebo. Those taking lower doses of the treatment showed no improvement compared to the placebo group, however.

While the pain reduction measured by these Phase 2 trials was statistically significant, it’s unclear how meaningful the drug’s benefits were to patients, with a commentary accompanying the study describing the treatment effect as “small.” But the study authors noted that participants on a high dose of VX-548 were less likely to prematurely stop their treatment because it wasn’t working than those on placebo or participants given a combination of two common painkillers, acetaminophen and hydrocodone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Group behind ProMed defends move to subscription

WSS

Readout Newsletter: Bluebird, CVS, Contineum

2 officers injured in shooting in Orlando, police say

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Leading voice in opioid treatment defends methadone clinic system

Physicians and social media: If you see something, say something?

Group behind ProMed defends move to subscription

focus

hotspot

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AstraZeneca to buy developer of next

How to save PrEP access — and even expand it

Medicare slashes safety net hospital payments by nearly $1 billion

Medical leaders decry Supreme Court decision on affirmative action

Colonoscopy prep: Liquid

Hollywood unions extend contract negotiations for actors

Health AI adoption puts security, privacy startups on investors' radar

United colonoscopy coverage change 'may cost lives,' doctors say

Late stage cancers on the rise after pandemic delayed screenings

hotspot

App could help diagnose ear infections more accurately — and at home

Biotech startup Celsius cuts 75% of staff ahead of first trial start

The a glaring gap in research on serious mental illness and primary care

Plastic surgeons increase patient psychiatric screenings

How to ethically and practically extend health care to all

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Wikipedia

focus

leisure time

focus